MX2024007629A - Compuesto como inhibidor de fak y uso del mismo. - Google Patents
Compuesto como inhibidor de fak y uso del mismo.Info
- Publication number
- MX2024007629A MX2024007629A MX2024007629A MX2024007629A MX2024007629A MX 2024007629 A MX2024007629 A MX 2024007629A MX 2024007629 A MX2024007629 A MX 2024007629A MX 2024007629 A MX2024007629 A MX 2024007629A MX 2024007629 A MX2024007629 A MX 2024007629A
- Authority
- MX
- Mexico
- Prior art keywords
- fak
- compound
- general formula
- compound represented
- fak inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111574916 | 2021-12-21 | ||
| CN202210377379 | 2022-04-11 | ||
| PCT/CN2022/138955 WO2023116527A1 (zh) | 2021-12-21 | 2022-12-14 | 作为fak抑制剂的化合物及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007629A true MX2024007629A (es) | 2024-07-04 |
Family
ID=86901291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007629A MX2024007629A (es) | 2021-12-21 | 2022-12-14 | Compuesto como inhibidor de fak y uso del mismo. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20260159499A1 (enExample) |
| EP (1) | EP4455139A4 (enExample) |
| JP (1) | JP2024547090A (enExample) |
| KR (1) | KR20240128695A (enExample) |
| CN (1) | CN118525015A (enExample) |
| AU (1) | AU2022422848A1 (enExample) |
| CA (1) | CA3238851A1 (enExample) |
| MX (1) | MX2024007629A (enExample) |
| WO (1) | WO2023116527A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026086879A1 (zh) * | 2024-10-25 | 2026-04-30 | 应世生物科技(南京)有限公司 | Fak抑制剂 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2702647C (en) * | 2007-01-31 | 2016-03-22 | Ym Biosciences Australia Pty Ltd | Thiopyrimidine-based compounds and uses thereof |
| WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| AR074210A1 (es) * | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina como inhibidores de ptk2-quinasa |
| BR112016000195A8 (pt) * | 2013-07-11 | 2019-12-31 | Acea Biosciences Inc | compostos heterocíclicos, composição farmacêutica, combinação, seu uso, e método para inibir uma atividade da tirosina quinase btk ou jak, egfr, alk, pdgfr, blk, bmx/etk, flt3(d835y), itk, tec, txk, e suas respectivas vias |
| CN105330698B (zh) * | 2014-07-04 | 2019-05-28 | 齐鲁制药有限公司 | 螺环芳基磷氧化物和硫化物 |
| CN105601631A (zh) * | 2014-10-21 | 2016-05-25 | 北京艾莱英医药科技有限公司 | 2,4-二取代-5-氯嘧啶类衍生物、其制备方法及其在医药上的应用 |
| TWI726363B (zh) * | 2018-07-31 | 2021-05-01 | 大陸商蘇州亞盛藥業有限公司 | Fak/alk/ros1抑制劑與egfr抑制劑的組合治療癌症的方法 |
| CN118574825A (zh) * | 2022-02-28 | 2024-08-30 | 微境生物医药科技(上海)有限公司 | 作为fak抑制剂的化合物及其用途 |
-
2022
- 2022-12-14 CN CN202280084292.4A patent/CN118525015A/zh active Pending
- 2022-12-14 MX MX2024007629A patent/MX2024007629A/es unknown
- 2022-12-14 US US18/709,760 patent/US20260159499A1/en active Pending
- 2022-12-14 CA CA3238851A patent/CA3238851A1/en active Pending
- 2022-12-14 AU AU2022422848A patent/AU2022422848A1/en active Pending
- 2022-12-14 EP EP22909841.3A patent/EP4455139A4/en active Pending
- 2022-12-14 WO PCT/CN2022/138955 patent/WO2023116527A1/zh not_active Ceased
- 2022-12-14 JP JP2024537471A patent/JP2024547090A/ja active Pending
- 2022-12-14 KR KR1020247023925A patent/KR20240128695A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4455139A4 (en) | 2025-09-24 |
| CN118525015A (zh) | 2024-08-20 |
| EP4455139A1 (en) | 2024-10-30 |
| JP2024547090A (ja) | 2024-12-26 |
| CA3238851A1 (en) | 2023-06-29 |
| WO2023116527A1 (zh) | 2023-06-29 |
| AU2022422848A1 (en) | 2024-06-13 |
| US20260159499A1 (en) | 2026-06-11 |
| KR20240128695A (ko) | 2024-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202310378B (en) | Complement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof | |
| MX2023012054A (es) | Inhibidor derivado heterociclico y metodo de preparacion y su aplicacion. | |
| CR20240147A (es) | Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t | |
| MX2021006026A (es) | Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos. | |
| MX2022010795A (es) | Hidrato cristalino de un compuesto inhibidor de jak. | |
| MX2024001893A (es) | Compuestos heterociclicos y metodos de uso. | |
| MX2023012726A (es) | Compuestos heterociclicos y metodos de uso. | |
| GEAP202616866A (en) | 2-azabicyclo[2.2.1]heptane kras inhibitors | |
| WO2021147236A9 (zh) | 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用 | |
| MX2022015531A (es) | Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo. | |
| SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
| AU2020231934A8 (en) | Compounds useful in HIV therapy | |
| AU2020288567A8 (en) | Pyrrolopyrimidine compound and use thereof | |
| PH12022553498A1 (en) | Novel acid secretion inhibitor and use thereof | |
| MX2024002131A (es) | Inhibidores de la 17-beta-hidroxisteroide deshidrogenasa tipo 13 y metodos de uso de los mismos. | |
| ZA202304541B (en) | Cdk inhibitors and their use as pharmaceuticals | |
| MX2023003576A (es) | Compuesto como inhibidor de la akt cinasa. | |
| MX2022013890A (es) | Sintesis y derivados de acido boronico, formas polimorficas y usos terapeuticos de los mismos. | |
| MX2025001982A (es) | Inhibidores de kif18a y usos de estos | |
| ZA202400823B (en) | Inhibitors of transglutaminases | |
| WO2024046512A3 (zh) | 含氮大环类化合物及其制备方法和医药用途 | |
| ZA202400821B (en) | Inhibitors of transglutaminases | |
| MX2025012370A (es) | Compuesto de amida, composicion farmaceutica que comprende el compuesto y uso de esta | |
| MX2020004588A (es) | Inhibidor de proteasa de doble cabeza. | |
| MX2025004635A (es) | Sal y forma cristalina de derivado heterociclico inhibidor, y metodo de preparacion y uso de las mismas |